reports
Esperion’s Bempedoic Acid Receives Recommendation in 2025 ACC Scientif...
Esperion’s Bempedoic Acid Receives Recommendation in 2025 ACC Scientific Statement on Management of Peripheral Artery Disease in Adults With Diabetes – Bempedoic Acid Highlighted by ACC for LDL-C Lowering in Patients with Peripheral Artery Disease and Diabetes Based on Proven Cardiovascular and Limb Benefits – ANN ARBOR, Mich., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) welcomed the inclusion of bempedoic acid as a first-line, evidence-based therapy for LDL-C lowering for patients on maximally tolerated statins in the 2025 American College of Cardiology (ACC) Scientific ...
Arch Capital Group Ltd: 1 director
Two Directors at Arch Capital Group Ltd sold/gave away 265,759 shares at between 0.000USD and 93.907USD. The significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's di...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) ANN ARBOR, Mich., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on December 4, 2025, the Company granted three new employees (i) non-qualified stock options to purchase an aggregate of 380,000 shares of common stock, all of which were granted to John Harlow, the Company’s newly appointed Chief Commercial Officer, and (ii) 435,536 restricted stock units (RSUs), 424,536 of which were awarded to Mr. Harlow, under Esperion’s 2017 Inducement Equity Incentive Plan. The 2017 Inducement Equ...
UFP Technologies Announces CEO Succession Plan
UFP Technologies Announces CEO Succession Plan NEWBURYPORT, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (Nasdaq: UFPT), a contract development and manufacturing organization that specializes in single-use and single-patient medical devices, today announced that R. Jeffrey Bailly will retire as CEO at the Company’s next annual meeting on June 4, 2026. At that time, Mitchell Rock, President of the Company, will assume the CEO position and join the Company’s Board. To facilitate a smooth transition, Mr. Bailly will serve as Executive Chairman of the Board for the followin...
- Jonathan Moreland
TPVG TRIPLEPOINT VENTURE GROWTH BDC CORP
TPC TUTOR PERINI CORPORATION
SLGN SILGAN HOLDINGS INC.
RPD RAPID7 INC.
OPK OPKO HEALTH INC.
OHI OMEGA HEALTHCARE INVESTORS INC.
NCLH NORWEGIAN CRUISE LINE HOLDINGS LTD.
MTDR MATADOR RESOURCES COMPANY
GBCI GLACIER BANCORP INC.
FTAI FORTRESS TRANSPORTATION AND INFRASTRUCTURE INVESTORS LLC
FOXF FOX FACTORY HOLDING CORP.
EIG EMPLOYERS HOLDINGS INC.
ARCC ARES CAPITAL CORPORATION
RLMD RELMADA THERAPEUTICS
TREX TREX COMPANY INC.
VVV VALVOLINE INC.
KREF KKR REAL ESTATE FINANCE TRUST
HLNE HAMILTON LANE INCORPORATED CLASS A
SONO SONOS
VRCA VERRICA PHARMACEUTICALS
AMCR AMCOR PLC
AVTR AVANTOR
TSLX INC.
VLA SIXTH STREET SPECIALTY LENDING
MRVI INC.
FRSH ARBOR METALS
SG MARAVAI LIFESCIENCES HOLDINGS
TBBK FRESHWORKS INC.
QDEL SWEETGREEN INC
BHVN THE BANCORP
WEST INC.
SMRT QUIDEL CORP
CRVO BIOHAVEN LTD
NCDL WESTROCK COFFEE COMPANY LLC
GAM SMARTRENT INC
STRZ CERVOMED INC
GMRE NUVEEN CHURCHILL DIRECT LENDING CORP
OESX GENERAL DE ALQUILER DE MAQUINARIA
STARZ ENTERTAINMENT CORP
GLOBAL MEDICAL REIT INC.
ORION ENERGY SYSTEMS INC
UFP Technologies to Present and Host 1X1 Investor Meetings at the Pipe...
UFP Technologies to Present and Host 1X1 Investor Meetings at the Piper Sandler 37th Annual Healthcare Conference NEWBURYPORT, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (Nasdaq: UFPT) a contract development and manufacturing organization that specializes in single-use and single-patient medical devices, today announced that Chairman and Chief Executive Officer R. Jeffrey Bailly, President Mitchell C. Rock, and Chief Financial Officer Ron Lataille will participate in the upcoming Piper Sandler 37th Annual Healthcare Conference to be held in New York City December 1-4,...
- Jonathan Moreland
UEC URANIUM ENERGY CORP
TPVG TRIPLEPOINT VENTURE GROWTH BDC CORP
STAA STAAR SURGICAL CO.
OPK OPKO HEALTH INC.
LQDT LIQUIDITY SERVICES
LMAT LEMAITRE VASCULAR INC.
FAST FASTENAL COMPANY
BEN FRANKLIN RESOURCES INC.
SRTS SENSUS HEALTHCARE
RSSS RESEARCH SOLUTIONS
ULBI ULTRALIFE
EVLV EVOLV TECHNOLOGIES HLDGS INC
WEST WESTROCK COFFEE COMPANY LLC
SMRT SMARTRENT INC
NCDL NUVEEN CHURCHILL DIRECT LENDING CORP
SLS SELLAS LIFE SCIENCES GROUP INC
BATRK LIBERTY MEDIA CORP
ANNX ANNEXIN PHARMACEUTICALS AB (PUBL)
OESX ORION ENERGY SYSTEMS INC
Opko Health Inc: 1 director
A director at Opko Health Inc bought 580,000 shares at 1.326USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
Esperion Partner Otsuka Launches NEXLETOL® in Japan for the Treatment ...
Esperion Partner Otsuka Launches NEXLETOL® in Japan for the Treatment of Hypercholesterolemia – Company to Receive $90 Million Total Payment – – Third Largest Global Market for Cardiovascular Prevention Represents Significant Global Growth Opportunity for NEXLETOL – ANN ARBOR, Mich., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that Otsuka Pharmaceutical Co., Ltd. (Otsuka), the Company’s partner in Japan for the development and commercialization of NEXLETOL® (bempedoic acid) tablets, received National Health Insurance Price Listing and launched NEXLETOL for ...
- Jonathan Moreland
PPSI PIONEER POWER SOLUTIONS
PEB PEBBLEBROOK HOTEL TRUST
PCTY PAYLOCITY HOLDING CORP.
OPK OPKO HEALTH INC.
LOB LIVE OAK BANCSHARES
GOGO GOGO INC.
GLP GLOBAL PARTNERS LP
FLDM FLUIDIGM
FAST FASTENAL COMPANY
CPSI COMPUTER PROGRAMS & SYSTEMS INC.
CNS COHEN & STEERS INC.
MSM MSC INDUSTRIAL DIRECT CO. INC. CLASS A
INTT INTEST CORP.
MIRM MIRUM PHARMACEUTICALS
TSLX SIXTH STREET SPECIALTY LENDING
MYPS INC.
QDEL PLAYSTUDIOS INC
GTE QUIDEL CORP
ET GRAN TIERRA ENERGY INC.
MXF ENERGY TRANSFER LP
GDV THE MEXICO FUND
INC.
THE GABELLI DIVIDEND & INCOME TRUST
- Jonathan Moreland
TPVG TRIPLEPOINT VENTURE GROWTH BDC CORP
OPK OPKO HEALTH INC.
HUBB HUBBELL INCORPORATED CLASS B
CPSI COMPUTER PROGRAMS & SYSTEMS INC.
GAM GENERAL AMERICAN INVESTORS CO. INC.
KYN KAYNE ANDERSON MLP INVESTMENT CO.
SRTS SENSUS HEALTHCARE
AEYE AUDIOEYE INC
UTZ UTZ BRANDS INC (A)
CRVO CERVOMED INC
NEXT NEXTSOURCE MATERIALS INC.
SPRU SPRUCE POWER HOLDING CORP
FG F AND G ANNUITIES AND LIFE
HYMC INC.
FIG HYCROFT MINING HOLDING CORPORATION
STRZ FIGMA INC.
CRCL STARZ ENTERTAINMENT CORP
BATRK CIRCLE INTERNET GROUP INC.
ANNX LIBERTY MEDIA CORP
ANNEXIN PHARMACEUTICALS AB (PUBL)
OPKO Health to Participate in the Piper Sandler 37th Annual Healthcare...
OPKO Health to Participate in the Piper Sandler 37th Annual Healthcare Conference MIAMI, Nov. 19, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the Piper Sandler 37th Annual Healthcare Conference, being held December 2-4, 2025 at the Lotte New York Palace Hotel in New York City. Management will be holding one-on-one meetings with investors and will be participating in a fireside discussion on Wednesday, December 3rd at 12:00 p.m. Eastern time. Investors interested in scheduling a meeting with OPKO management should conta...
Esperion to Participate in Piper Sandler 37th Annual Healthcare Confer...
Esperion to Participate in Piper Sandler 37th Annual Healthcare Conference ANN ARBOR, Mich., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will present at the Piper Sandler 37th Annual Healthcare Conference in New York on December 3, 2025, at 3:30 p.m. ET. The live webcast can be accessed on the investor and media section of the Esperion . Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90 days. Esperion TherapeuticsEsperion...
- Jonathan Moreland
DEI DOUGLAS EMMETT INC
SPG SIMON PROPERTY GROUP INC.
OPK OPKO HEALTH INC.
MYE MYERS INDUSTRIES INC.
GOGO GOGO INC.
CPSI COMPUTER PROGRAMS & SYSTEMS INC.
AP AMPCO-PITTSBURGH
INBK FIRST INTERNET BANCORP
PRKR PARKERVISION INC.
MSEX MIDDLESEX WATER CO.
SONO SONOS
TMDX TRANSMEDICS GROUP
NML NEUBERGER BERMAN MLP INCOME FUND INC.
VLA ARBOR METALS
ACVA ACV AUCTIONS INC.
NRDY NERDY INC.
BHVN BIOHAVEN LTD
MNR MACH NATURAL RESOURCES LP
MXF THE MEXICO FUND
GF INC.
RMI THE NEW GERMANY FUND
LPSN INC.
RIVERNORTH OPPOR MUN INC FD INC
LIVEPERSON INC.
Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for t...
Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease ANN ARBOR, Mich., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that HLS Therapeutics Inc. (TSX: HLS), the Company’s partner in Canada for the development and commercialization of NILEMDO® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe), has received approval from Health Canada to market NILEMDO for the reduction of LDL-Cholesterol in Canadians at risk of cardiovascular disease. Commercial launch for ...
Middlefield Banc Corp. Announces 2025 Fourth-Quarter Cash Dividend Pay...
Middlefield Banc Corp. Announces 2025 Fourth-Quarter Cash Dividend Payment MIDDLEFIELD, Ohio, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Middlefield Banc Corp. (NASDAQ: MBCN) today announced that its Board of Directors declared a quarterly cash dividend of $0.21 per common share. The 2025 fourth-quarter dividend is payable on December 12, 2025, to shareholders of record on November 28, 2025. About Middlefield Banc Corp. Middlefield Banc Corp., headquartered in Middlefield, Ohio, is the Bank holding Company of The Middlefield Banking Company, with total assets of $1.98 billion at September 30, 202...
UFP Technologies Inc: 1 director
A director at UFP Technologies Inc sold 1,829 shares at 227.201USD and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...
Esperion Announces New Data from CLEAR Outcomes Highlighting Value of ...
Esperion Announces New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) in Oral and Poster Presentations at the AHA Scientific Sessions 2025 – Analysis of Patients from CLEAR Outcomes Receiving No Other Background Lipid Lowering Therapies, Bempedoic Acid Alone Reduced MACE-4 by 14% Compared to Placebo – – An Exploratory Analysis of CLEAR Outcomes Reports Patients Who Took Bempedoic Acid Were 42% Less Likely to Experience Venous Thromboembolism Events Compared to Placebo – ANN ARBOR, Mich., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) ANN ARBOR, Mich., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on November 4, 2025, the Company granted 23 new employees 77,650 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Incentive Plan. The 2017 Inducement Equity Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Esperion (or following a bona fide period of non-employment), as an inducement material to such indi...
Esperion Reports Third Quarter 2025 Financial Results and Provides Bus...
Esperion Reports Third Quarter 2025 Financial Results and Provides Business Update – Q3 2025 Total Revenue Grew 69% Y/Y to $87.3 Million – – Q3 2025 U.S. Net Product Revenue Grew 31% Y/Y to $40.7 Million – – Reached Settlement Agreement with ANDA Filer, Dr. Reddy’s Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Prior to April 2040 – – Bempedoic Acid Received Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidemias – – Partner Otsuka Received Regulatory Approval and Favorable Preliminary...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.